News & Events
1859 Welcomes Sanket Agrawal as New CEO
1859, an AI-based drug discovery company, appoints new CEO to drive strategic vision, expand development pipeline, and forge industry partnerships.
1859 Inc. Launches with $40 Million Series A to Industrialize New Medicine Discovery by Combining Artificial Intelligence and Empirical Screening Data at Scale
1859 Inc. is a platform company combining artificial intelligence and empirical screening data at scale to discover new small molecule medicines for emerging disease targets. The company partners with pharmaceutical and biotech companies, and academic institutions to dramatically shorten the time and resources needed to identify and screen high-potential compounds for future exploration and development.